MetaCap

BlossomHill Therapeutics (BLSM) vs Monopar Therapeutics (MNPR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Monopar Therapeutics is the larger company by market cap ($467.6 million vs $461.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLSM-9.31%MNPR-42.12%
+73%+12%-50%
Aug 7, 20261 yearNov 20, 2026
BLSM-9.31%MNPR-42.12%
+66%+9%-47%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLSM versus MNPR key metrics
MetricBLSMMNPR
Share price$14.51$69.00
Market cap$461.20M$467.60M
1-day change+0.69%-1.84%
YTD return—+5.67%
1-year return—-24.64%
5-year return—+184.54%
EPS (TTM)$-10.38$-2.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)—$-13.72M
52-week high$27.99$124.82
52-week low$11.02$50.07
Distance from 52-week high-48.16%-44.72%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+143.97%+88.65%
Average volume193.15K151.83K
Shares outstanding31.78M6.78M
Employees6922
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BlossomHill Therapeutics

BLSM stock →

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Monopar Therapeutics

MNPR stock →

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.

Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees

BLSM vs MNPR FAQ

Which is bigger, BlossomHill Therapeutics or Monopar Therapeutics?

Monopar Therapeutics (MNPR) is larger, with a market capitalization of $467.60M compared with $461.20M for BlossomHill Therapeutics (BLSM).

Are BlossomHill Therapeutics and Monopar Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons